Adtran brings its latest coherent innovation to OFCnet multi-vendor demo
7.3.2023 16:00:00 EET | Business Wire | Press release
Adtran®, Inc., (NASDAQ:ADTN), the leading provider of open and disaggregated networking solutions, today announced that its latest coherent innovation will be showcased at OFC as part of OFCnet. The demo reveals how the Adtran FSP 3000 open line system (OLS) can bring new levels of flexibility to optical networks by enabling optimized, tailored spectrum services. In collaboration with Acacia, Cisco, Coherent Corp., Corning, EXFO, Nokia and VIAVI Solutions, Adtran will showcase 100ZR, 200Gbit/s, 400Gbit/s OpenZR+ and 800Gbit/s connectivity. The FSP 3000 DCI OLS is also playing a key role in the OIF 400ZR demo at OFC.
“Our demo shows how the spectrum-as-a-service concept has the potential to revolutionize the way operators utilize their fiber resources. It highlights how it’s possible to slice up the network even in a metro environment. With fully flexible spectrum allocation, operators can provide a wide variety of differentiated services and ensure they leverage the full capacity of their infrastructure. Not only will this help tackle ever-increasing data demand, but it also offers a new route to revenue growth,” said Jörg-Peter Elbers, head of advanced technology at Adtran. “Our compact FSP 3000 OLS is the key to realizing the full benefits of this open and flexible approach. It removes the limits of fixed channel grids so that untapped spectrum can be put to work.”
The coherent innovation demo features a three-node ring network with flexgrid ROADMs in the Adtran, Coherent Corp. and OFCnet booths. Adtran’s FSP 3000 OLS is used to ensure strict separation between users while minimizing the unused bandwidth between their spectrum services, and its high-resolution flexgrid ROADMs provide optical channel monitoring, demarcation and passband optimization for all spectrum services. Also on display is the Adtran TeraFlex™ CoreChannel™, which transports 100Gbit/s and 400Gbit/s Ethernet client signals over a coherent 800Gbit/s signal. In combination with Adtran’s MicroMux™, the terminal shows the transmission of 10Gbit/s services without any footprint increase. What’s more, Adtran’s OpenFabric+™ is being used to demonstrate 200Gbit/s connectivity.
“One of the most exciting elements of this demo is showcasing the value of our Coherent 100ZR. To meet growing traffic demands, network operators need to upgrade their edge aggregation infrastructure to support 100Gbit/s rates. However, this can be a costly and complex process. With its QSFP28 form factor, our Coherent 100ZR easily fits into existing host platforms and can operate over any optical network infrastructure. This facilitates the adoption of 100Gbit/s coherent technology at the network edge without major infrastructure changes and at an affordable price,” commented Ross Saunders, GM of Optical Engines, Adtran. “With a new purpose-built DSP, a standards-compliant QSFP28 form factor, and 5W power consumption, our Coherent 100ZR opens the door to widespread rollout of 100Gbit/s coherent technology at the optical edge.”
About Adtran
Adtran, Inc. is a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. Adtran, Inc. is a wholly-owned subsidiary of ADTRAN Holdings, Inc. (NASDAQ:ADTN and FSE: QH9). Find more at Adtran, LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005685/en/
Contact information
Published by
Adtran, Inc.
www.adtran.com
For media
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors
Rhonda Lambert
t +1 256-963-7450
investor@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 15:40:00 EEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 15:30:00 EEST | Press release
ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document processing and recognition technology, which uses advanced machine learning to process large volumes of documents with high speed and accuracy, helping organizations detect fraud earlier, prevent losses and improve outcomes. The combined business becomes one of the largest AI-native digital trust infrastructures serving regulated industries, with more than 300 enterprise customers and more than 110 billion digital interactions processed annually across the U.S., Europe, the Middle East and Australia. Customers include many of the world's
SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 15:04:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every aspect of well delivery through a technology-enabled operating model. It combines digital drilling workflows with au
Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 15:03:00 EEST | Press release
Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 14:00:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales (SAPS-H+D), once daily 60 mg remlifanserin demonstrated a change of -12.6 versus a -10.4 change for placebo at week 6, yielding a standardized effect size of 0.26 (p=0.0603). For the key secondary endpoint, Clinical Global Impression – Severity (CGI-S-ADP), the 60 mg dose achieved a change from baseline of -1.3 versus a change of -0.9 for placebo at week 6, yielding a standardized effect size of 0.37 [p=0.0077 (nominal)]. On both efficacy measures, the difference in the 60 mg dose versus placebo increased through the 6-week treatment period. The 30 mg dose showe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom